| Ticker: | NUVB |
| Current Price: | $3.99 |
| % Daily Change: | -1.72% |
| Volume (1,000s): | 3,086.62 |
| Average Volume (1,000s): | 6,411.80 |
| Market Cap (M): | $1,404.55 |
| 1/2/2024 Price: | $2.89 |
| Change Since Inception: | 38.06% |
Nuvation Bio Inc.
1500 Broadway
Suite 1401
New York, NY 10036
United States
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutic candidates for oncology. Its lead product candidate is taletrectinib, an ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. The company is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 2 clinical trials; NUV-1511, a drug-drug conjugate for use in chemotherapy agent that suppresses the growth of various advanced solid tumors; and NUV-868, a binding domain 2 bromodomain and extra-terminal inhibitor that inhibits bromodomain-containing protein 4. The company was founded in 2018 and is headquartered in New York, New York.